Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

Sulfonylureas are a cornerstone of type 2 diabetes therapy despite interindividual variability in response. Despite well‐documented sex‐based differences, pharmacogenomic and genome‐wide association studies (GWAS) have largely overlooked sex as a biological variable. We conducted the first sex‐stratified GWAS of hemoglobin A1c (HbA1c) response to sulfonylureas in Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial participants ( N = 871). Variants meeting genome‐wide ( P < 5.0 × 10 –8 ) and suggestive ( P < 5.0 × 10 –6 ) significance were assessed for replication in the Pharmacogenomics of Metformin (PMET1) cohort. Replicated variants were further analyzed in the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR‐MGH) cohort to assess acute insulin and glucose responses to a single glipizide dose. Genome‐wide significant loci with sex‐specific effects were identified: KAZN , KIF2B , SLC39A10 , and SPINK5 (combined‐sex); CRACR2A , KCNK2 , and TENM2 (male‐only); and NACPH2 (female‐only). Two suggestive variants in the TMEM64 / NECAB1 locus, associated with reduced HbA1c response to sulfonylureas in the male‐only ACCORD analysis, were directly replicated in the PMET1 male‐only cohort. In SUGAR‐MGH, one replicated variant (rs6471250‐C) was significantly associated with reduced peak insulin in males ( P = 0.035) but not females ( P = 0.40), demonstrating sex‐specific functional effects. This study identified statistically supported and biologically plausible loci with prior evidence linking nearby genes to pathways relevant to sulfonylurea action, including insulin secretion, insulin regulation/sensitivity, calcium signaling, potassium‐channel biology, and glucose transport. The findings highlight sex‐specific differences in sulfonylurea response, providing mechanistic insights and underscoring the importance of sex‐specific precision medicine. Identification of genetic variants influencing sex‐specific response could inform dosing to optimize sulfonylureas.